XBIT

Investor Moves

Investor	Portfolio Value	Portfolio Change	Position Change	Avg Buy Price	Current Price
Ken GriffinCitadel Advisors $-44.0K ExitQ1 2026 $44k -- $2.44
Ken GriffinCitadel Advisors $17.4K AddQ3 2025 $17k -- $2.44
Ken GriffinCitadel Advisors $17.4K AddQ3 2025 $17k -- $2.44
Ken GriffinCitadel Advisors $-51.4K ExitQ1 2025 $51k -- $2.44
Ken GriffinCitadel Advisors $-51.4K ExitQ1 2025 $51k -- $2.44
Ken GriffinCitadel Advisors $-78.6K ExitQ3 2024 $79k -- $2.44

News

defenseworld.netComparing XBiotech (NASDAQ:XBIT) & IN8bio (NASDAQ:INAB)defenseworld.netMar 26

defenseworld.netHead-To-Head Comparison: XBiotech (NASDAQ:XBIT) and Psyence Biomedical (NASDAQ:PBM)defenseworld.netMar 19

Trade XBIT

About XBiotech Inc.

XBiotech Inc. is a biopharmaceutical firm specializing in the discovery, development, and commercialization of True Human monoclonal antibodies. Their primary focus involves building a robust pipeline of product candidates aimed at combating both inflammatory and infectious diseases. Furthermore, the company is advancing interleukin-1 alpha-based therapies, which are designed to address a broad spectrum of medical conditions such as cancer, stroke, heart attack, and arthritis. Interleukin-1 alpha itself plays a crucial role in biological processes like tissue breakdown, angiogenesis, blood clot formation, malaise, muscle wasting, and inflammation. Additionally, XBiotech is developing a True Human COVID-19 therapy specifically targeting mutant strains of the virus. Established in 2005, XBiotech Inc. maintains its headquarters in Austin, Texas.

CEO: Sushma Shivaswamy
IPO Date: Apr 15, 2015

Market Data

Open: $2.39
High: $2.39
Low: $2.36
Volume: 10K
52W High: $3.61
52W Low: $2.09

Valuation

Market Cap: $72M
Enterprise Value: $-43M

Financials

Free Cash Flow: $-40M
Revenue: $0
Net Income: $-46M
Cash: $126M
Debt: $0

Events

EarningsMay 14

EPS est. 0.03 · actual -0.18